Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes

Diabetes Care

Volumn 33, Issue 6, 2010, Pages 1193-1199

  Li, Rui ^a   Zhang, Ping ^a   Barker, Lawrence E ^a   Hoerger, Thomas J ^b  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DEATH; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; ISCHEMIC HEART DISEASE; LIFESPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STROKE; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; TIME;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 77956072686     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-1888     Document Type: Article

References (25)

1. Cull CA, Neil HAW, Holman RR. Changing aspirin use in patients with type 2 diabetes in the UKPDS. Diabet Med 2004;21:1368-1371 (Pubitemid 39620064)
2. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br J Med 2002;324:71-86
3. U.S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002;136:157-160
4. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 2000;23(Suppl. 1):S61-S62
5. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006;144:326-336
6. Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women, a cost-utility analysis. Arch Intern Med 2007;167:290-295 (Pubitemid 46256548)
7. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002;287:2542-2551
8. Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 2004;140:689-699 [see comment]
9. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Abrozek AS, Dong F, Manninen D, Garfield SA, Copley-Merriman C, Maier W, Eastman JF, Kotsanos J, Cowie CC, Harris M. Model of complications for NIDDM, I: model construction and assumptions. Diabetes Care 1997;20:725-734
10. Eastman RC, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, Manninen D, Garfield SA, Copley-Merriman C, Maier W, Eastman JF, Kotsanos J, Cowie CC, Harris M. Model of complications of NIDDM: II. model construction and assumptions. Diabetes Care 1997;20:735-744
11. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the coronary heart disease policy model. Am J Public Health 1987;77:1417-1426
12. American Diabetes Association Consensus Panel: Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-2265
13. De Berardis G, Sacco M, Strippoli GFM, Pellegrini F, Graziano G, Tognoni G, Nicolucci A. Aspirin for primary prevention of cardiovascular events in people with diabetes:meta-analysis of randomised controlled trials. Br J Med 2010;339:b4531
14. Antithrombotic Trialists (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860
15. Brandle Ml, Zhou H, Smith BR, Marriott D, Burke R, Tabaei BP, Brown MB, Herman WH. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-2304
16. Hoerger TJ. Using costs in cost-effectiveness models for chronic diseases. Med Care 2009;47(Suppl. 1):S21-S27
17. Coffey JT, Zhou H, Burke MR, Tabaei BP, Engelgau MM, Kaplan RM, Herman WH. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238-2243 (Pubitemid 41071034)
18. Augustovski FA, Cantor SB, Thach CT, Spann SJ. Aspirin for primary prevention of cardiovascular events. J Gen Intern Med 1998;13:824-835
19. Saaddine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, Imperatore G, Narayan KM. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann Intern Med 2006;144:465-474
20. Laupacis A, Deeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-481
21. Gaspoz J-M, Goxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink M. Cost effectiveness of aspirin, clopidogrel, or both fro secondary prevention of coronary heart disease. N Engl J Med 2002;346:1800-1806
22. Kahn R, Robertson RM, Smith R, Eddy D: The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008;118
23. Woods RL, Tonkin AM, Nelson MR, Britt HC, Reid CM. Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes? Med J Australia 2009;190:614-615
24. Belch J, MacCuish A, Campbell I. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br J Med 2008;337:a1840
25. Ogawa H, Nakayama M, Marimato T, Uemura S, Kanauchi M, Doi N, Jinnonchi H, Sugiyamak S, Saito Y. low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141